Posting of Annual Report & Notice of Annual General Meeting
LONDON / ACCESSWIRE / May 28, 2019 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2018 ("2018 Annual Report"), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website:
https://hemogenyx.com/investors/annual-and-half-year-reports/default.aspx
The 2018 Annual Report will be posted to shareholders today.
The AGM is to be held on 28 June 2019 at 11am at the offices of Osborne Clarke LLP, One London Wall, London EC2Y 5EB.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|||
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|||
|
Sir Marc Feldmann, Executive Chairman |
|
||
|
|
|
||
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
||
|
Matthew Johnson, Vadim Alexandre, Soltan Tagiev |
|
||
|
|
|
||
|
Peterhouse Corporate Finance Limited |
Tel: +44 (0)20 7469 0930 |
||
|
Lucy Williams, Duncan Vasey |
|
||
|
|
|
||
|
US Media enquiries |
Tel: +1 (323) 646-3249 |
||
|
Lowell Goodman |
|
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
SOURCE: Hemogenyx Pharmaceuticals plc